Chemoradiotherapy in Unresectable Esophageal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Esophageal CancerChemoradiotherapyAlbumin-bound PaxlitaxelUnresectable Malignant Neoplasm
Interventions
RADIATION

Radiotherapy

59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.

DRUG

Albumin-Bound Paclitaxel

100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.

DRUG

Cisplatin

25mg/m2 weekly,by intravenous infusion in 5-6 weeks.

Trial Locations (5)

100021

RECRUITING

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

210009

RECRUITING

Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University, Nanjing

210029

RECRUITING

Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing

410031

RECRUITING

Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

455001

RECRUITING

Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT04278287 - Chemoradiotherapy in Unresectable Esophageal Cancer | Biotech Hunter | Biotech Hunter